Five-day deployment drives card payment success to 85%, digital wallet success to 90% and several hundred thousand dollars in first-month GMV

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ — As AI companies compete on models, features and user experience, payment infrastructure is becoming an increasingly important factor in whether global demand converts into revenue.

Subotiz, a subscriptions, checkout and compliance platform for AI, SaaS and digital businesses, today announced that it helped a fast-growing AI creative platform increase overall payment success by 42% after launching its global payment infrastructure in five business days.

Following deployment, card payment success stabilized at approximately 85%, while Apple Pay and Google Pay success rates reached as high as 90%. The platform also generated several hundred thousand dollars in gross merchandise value during its first month.

The AI company had built a competitive product and attracted users across multiple markets, but its payment experience was holding back growth. Failed transactions, limited local payment options and checkout friction were causing users to drop off before completing their subscriptions.

An internal review found that one competitor’s advantage was not stronger AI technology, but a smoother payment and subscription experience.

“We initially viewed payments as a back-end issue, but the data showed they were directly affecting conversion and our ability to compete,” said Michael W., Founder & CEO of the platform. “Subotiz delivered a complete solution in five days and continues to support us around the clock.”

Subotiz developed a tailored solution covering global card acceptance, digital wallets, multicurrency transactions, subscription management and regional payment optimization. KYC and KYB reviews ran in parallel with technical integration, significantly reducing the time required to go live.

After launch, Subotiz analyzed transaction and failed-payment data to identify conversion gaps by market and payment method. The findings were used to improve payment routing, prioritize local wallets and refine the checkout experience.

“AI companies can build products faster than ever, but monetization often becomes the next bottleneck,” said Adam Mawdesley, CRO at Subotiz. “Our goal is to remove payment complexity and help digital businesses convert more global demand into recurring revenue.”

About Subotiz

Subotiz is a next-generation payment and revenue infrastructure platform designed for global digital businesses. By combining payments, subscription management, usage-based billing, tax and compliance automation, and fraud prevention into a unified platform, Subotiz enables SaaS, AI, eCommerce, and platform businesses to scale globally with greater operational efficiency and revenue flexibility. Learn more at www.subotiz.com.

BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ — KPJ Healthcare Berhad (“KPJ Healthcare” or “the Group”) today launched its first Orthopaedic and Rheumatology Centre of Excellence (“CoE”) at KPJ Penang Specialist Hospital (“KPJ Penang”), marking the third CoE under the KPJ Health System (“KPJHS”). As Malaysia’s first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (“JCorp”) said, “Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase.”

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare’s long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital’s role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia’s first AI-assisted remote telewound care programme.

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia’s first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins.

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ — Human Longevity, Inc. (HLI), a precision health and longevity technology company, today announced the availability of Genomics for All, a clinical-grade whole genome sequencing product priced at $599. The offering sequences all 6.4 billion base pairs of an individual’s DNA and delivers AI-interpreted results through the HLI app, with no clinic visit required.

Unlike consumer ancestry tests, which analyse less than 0.02% of the genome using SNP chip technology, Genomics for All sequences the entire genome at 30x clinical-grade depth, the coverage standard required for medically meaningful interpretation. The result is a fundamentally different class of information: one capable of identifying inherited disease risk across more than 10,000 genetic variants, flagging pharmacogenomic markers that affect how individuals respond to common medications including statins and GLP-1 receptor agonists, and screening for carrier status in hereditary conditions. The report also covers health-related traits across nutrition, metabolism, and exercise response.

A central feature of the product is its AI-powered re-analysis capability. Because the genome itself does not change, HLI re-analyses each client’s genomic data on an ongoing basis as new research is published, new disease-gene associations are identified, and clinical guidelines are updated. When a new clinically relevant finding emerges, HLI proactively alerts affected clients, often within 24 hours of publication. This transforms a one-time sequencing event into a continuously evolving health resource.

“Our founder Dr. Venter helped make it possible for humanity to read the human genome,” said Wei-Wu He, Ph.D., Chairman and CEO of Human Longevity. “With Genomics for All, we are continuing that vision by helping more people understand what their genome may mean for their long-term health. Our goal is not to replace physicians or make deterministic predictions, but to provide better information that can support more informed conversations, earlier awareness, and more personalised care.”

Genomics for All sits within a broader AI-driven platform that HLI has been building for over a decade. In May 2026, HLI announced the launch of Human Life Foundation Models, Inc. (HLFM), a dedicated AI entity developed in partnership with Insilico Medicine, a clinical-stage generative AI biotechnology company. The multimillion-dollar collaboration aims to develop what the companies describe as the industry’s first large-scale AI foundation model dedicated to longevity science, drawing on HLI’s multimodal clinical and genomic datasets collected across more than 10,000 clients to identify the biological mechanisms of aging and enable predictive healthcare.

Genomics for All is the entry-level offering in HLI’s broader suite of precision health programs, which also includes more comprehensive assessments combining advanced imaging, biomarker panels, and clinician-guided care. The scientific advisory board includes Nobel laureates Dr. Geoffrey Hinton and Dr. Michael Levitt.

Genomics for All is available now at humanlongevity.com/genomics for $599.

About Human Longevity, Inc.
Human Longevity, Inc. is a precision health company focused on helping individuals better understand and manage long-term health through genomics, AI-supported interpretation, advanced diagnostics, and clinician-guided care. Founded in 2013 by Dr. J. Craig Venter and other life sciences leaders, the company has invested approximately $600M in research and worked with more than 10,000 clients across its clinics in San Diego and San Francisco. HLI’s programs include Genomics for All, Executive Health, 100+ Care, and 100+ Concierge. For more information, visit www.humanlongevity.com.

Brand’s largest brick-and-mortar expansion to date brings roadside emergency power off Amazon and onto Walmart shelves nationwide

SAN FRANCISCO, California, Aug. 4, 2026 /PRNewswire/ — GOOLOO, a global leader in portable power and roadside safety solutions, today announced the in-store launch of three of its best-selling jump starters — the GOOLOO A3X, GOOLOO G7X, and GOOLOO GE1500X — now available at approximately 4,000 Walmart stores across the United States. The rollout marks GOOLOO’s largest brick-and-mortar expansion to date, bringing the brand’s roadside emergency technology from online marketplaces directly to shoppers nationwide.

“Nearly half of the more than 32 million roadside assistance calls AAA receives each year involve dead batteries, flat tires, or lockouts. We wanted these three jump starters within arm’s reach of shoppers, not a shipping label away,” said Michael, General Manager at GOOLOO.

Until now, GOOLOO’s jump starters have been sold primarily through e-commerce channels. Their arrival at Walmart gives U.S. drivers same-day access to emergency power products, addressing a common frustration among customers who need battery assistance immediately rather than waiting on shipping.

The three products now available at Walmart include:

GOOLOO A3X 3000A Jump Starter with Air Compressor 

Designed as an all-in-one roadside solution, the A3X combines emergency jump-starting capability with a built-in tire inflator, helping drivers handle two of the most common roadside situations: dead batteries and low tire pressure.

Featuring automatic shut-off inflation, emergency lighting, USB power functionality, and GOOLOO’s SUPERSAFE™ protection system with multiple layers of battery safety protection, the A3X provides drivers with confidence and convenience in one compact device.

GOOLOO G7X 3000A Jump Starter 

The G7X introduces a new approach to everyday jump starter design by combining emergency starting capability with portable charging convenience.

Its integrated USB-C 45W fast-charging cable serves as both a built-in charging solution and a compact carry design feature, allowing users to charge smartphones, including the latest USB-C devices, and select laptops.

By increasing everyday usability beyond emergency situations, the G7X transforms the traditional jump starter from a product stored away for occasional emergencies into a practical portable power companion.

GOOLOO GE1500X 1500A Jump Starter

Designed for everyday drivers, the GE1500X delivers reliable emergency starting power with a compact and easy-to-use design.

Featuring emergency lighting, USB power functionality, and advanced safety protections, the GE1500X provides dependable roadside support for daily driving needs.

The GE1500X offers 1500A peak current for vehicles up to 6.0L gas or 4.0L diesel engines, a 400-lumen emergency flashlight with SOS mode, and UL 2743 / c-TUV-us certified safety protections.

All three jump starters are available now at Walmart stores nationwide and on Walmart.com, in addition to GOOLOO’s existing online retail channels.

About GOOLOO

GOOLOO is a leading global automotive roadside safety ecosystem brand specializing in high-performance lithium-ion portable jump starters, tire inflators, and multi-functional emergency tools. With its patented technologies SUPERSAFE®, JUMPCORE™ and TOOLCORE™, it has been serving millions of customers and drivers for over 12 years.

BUKIT MERTAJAM, Malaysia, Aug. 3, 2026 /PRNewswire/ — KPJ Healthcare Berhad (“KPJ Healthcare” or “the Group”) today launched its first Orthopaedic and Rheumatology Centre of Excellence (“CoE”) at KPJ Penang Specialist Hospital (“KPJ Penang”), marking the third CoE under the KPJ Health System (“KPJHS”). As Malaysia’s first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (“JCorp”) said, “Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase.”

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare’s long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital’s role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia’s first AI-assisted remote telewound care programme.

ENDS

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia’s first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.